Mark I Evans

Prof. Mark I Evans

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
MEMark I Evans
Mark I Evans
RWRonald Wapner
Ronald Wapner
RBRichard L. Berkowitz
Richard L. Berkowitz

1 February 2014 in Fetal Diagnosis and Therapy
Verified
Journal Article
Open access
PDF file
MEMark I Evans
Mark I Evans
SAStephanie Andriole
Stephanie Andriole
DBDavid W. Britt
David W. Britt
Fetal reduction (FR) began in the 1980s to salvage the pregnancies of couples needing fertility therapy who were finally successful but with too many fetuses. Since then, it has gone from a rarity performed in only the highest risk situations to an integral fail-safe of infertility practice. Our understanding of the problems of multiple and premature births has increased - even twins carry 4-5 times more risk than singletons. Evaluation of fetuses before FR has permitted more intelligent choices and improved resultant outcomes. We now perform chorionic villus sampling in approximately 85% of cases, obtain fluorescent in situ hybridization (FISH) results overnight, and then perform FR the next day. Decisions about which to reduce prioritize anomalies, but now can include fetal gender in the decision process, as couples are now just as likely to want girls as boys. In Mendelian cases, sophisticated molecular analyses permit diagnoses before FR, and new uses such as paternity analysis can be performed. Ethical arguments have also evolved; as with many technologies in which the start was for only ‘life or death cases', FR has also moved into ‘quality of life' issues. FR of twins to a singleton now compromise about 30% of our cases.

24 July 2007 in Fetal Diagnosis and Therapy
Verified
Journal Article
Closed access
MEMark I Evans
Mark I Evans
HDHilde Van Decruyes
Hilde Van Decruyes
KNKypros Herodotos Nicolaides
Kypros Herodotos Nicolaides
Objective: First-trimester aneuploidy screening is in transition from the phase of ‘development’ to that of ‘diffusion.’ As with all other technologies, there is risk of diminished performance until newer centers are well experienced. Typically, inexperienced sonographers under-measure nuchal translucency (NT), and experience, training and continual monitoring of data are needed to ensure that measurements do not deviate. Here we assess the impact of systematic under-measurement on abnormality detection. Study Design: Actual NT measurements from 13,887 normal fetuses, 82 with trisomy 21 (T21) and 61 with other abnormalities (OA) with birth outcome data were mathematically modified to show either a 25% or 0.5-mm decrease in measurement. The impact upon sensitivity and screen-positive rates were assessed. Results: Reducing the NT measurements of T21 and OA cases lowers the sensitivity from 81.7 and 70.5%, respectively, to 67.1 and 62.3% (p < 0.01). If normals are correspondingly lowered, then the screen-positive rates are reduced from 6.9 to 2.0 and 2.5%. To maintain the same screen-positive rates and sensitivity, the risk threshold would have to be increased from 1/300 to 1/556. Conclusion: Minor inaccuracies in NT measurements as small as 25% or 0.5 mm will have very significant negative impacts upon abnormality detection, reducing detection rates by 18% (81.7 to 67.1%). Just as it is completely accepted that laboratory measurements require standardization and quality assurance, NT measurements, because they are used in an algorithm, need to be treated with the same rigor. That way the published data from centers that have developed such screening can be applied by other operators at other sites when counseling their patients.

1 August 2005 in Seminars in Perinatology
Verified
Journal Article
Closed access
MEMark I Evans
Mark I Evans
RWRonald J. Wapner
Ronald J. Wapner

1 July 2010 in Seminars in Reproductive Medicine
Verified
Journal Article
Closed access
PDF file
MEMark I Evans
Mark I Evans
DBDavid W Britt
David W Britt
Multifetal pregnancy reduction (MFPR) was developed over 20 years ago to rescue higher-order multifetal pregnancies and has become a major component of improving the outcomes in infertility therapies. By definition, MFPR will always be controversial, but opinions do not follow the traditional “pro-life/pro-choice” dichotomy that has sabotaged the more generalized abortion debate. If one defines success as a healthy mother and healthy offspring, clearly, with multiples, fewer are always safer. The ethical issues surrounding MFPR are for most people not a clear black-or-white but varying shades of gray. The ethical principle of proportionality takes precedence (i.e., trying to obtain the most good for the least harm while looking for areas of moral compromise to achieve the best outcomes).

19 September 2005 in Prenatal Diagnosis
Verified
Journal Article
Closed access
PDF file
MEMark I Evans
Mark I Evans
DCDoina Ciorica
Doina Ciorica
DBDavid W. Britt
David W. Britt
JFJohn C. Fletcher
John C. Fletcher